Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy
Standard
Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. / Buhmann, Carsten; Hilker, R; Lingor, P; Schrader, C; Schwarz, J; Wolz, M; Reichmann, H.
In: J NEURAL TRANSM, Vol. 124, No. 8, 08.2017, p. 1005-1013.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy
AU - Buhmann, Carsten
AU - Hilker, R
AU - Lingor, P
AU - Schrader, C
AU - Schwarz, J
AU - Wolz, M
AU - Reichmann, H
PY - 2017/8
Y1 - 2017/8
N2 - Levodopa/carbidopa intestinal gel (LCIG) infusion is an effective escalating therapy in patients with Parkinson disease (PD) suffering from motor fluctuations and dyskinesia. Levodopa/carbidopa given continuously as infusion provides an optimized application of the most effective and best tolerable antiparkinsonian drug. It has been proven to have a superior motor effect compared with oral levodopa and to improve also non-motor symptoms. However, invasiveness, discomfort resulting from carrying an external device, and side effects associated with the way of administration limit its application in PD patients. At present, there are no guidelines that delineate to which patients LCIG should be offered as monotherapy, in combination with oral and/or transdermal medication, or as additional therapy to deep brain stimulation (DBS). Based on clinical studies, we propose an expert consensus for neurologists addressing the question when LCIG therapy should be recommended and in which cases LCIG infusion is suggested in combination with other antiparkinsonian drugs and/or DBS. We describe how LCIG should be initiated and what we consider necessary for clinical follow-up. We suggest an algorithm facilitating decision-making with respect to the currently available invasive PD therapies, namely infusion with subcutaneous apomorphine, LCIG, and DBS.
AB - Levodopa/carbidopa intestinal gel (LCIG) infusion is an effective escalating therapy in patients with Parkinson disease (PD) suffering from motor fluctuations and dyskinesia. Levodopa/carbidopa given continuously as infusion provides an optimized application of the most effective and best tolerable antiparkinsonian drug. It has been proven to have a superior motor effect compared with oral levodopa and to improve also non-motor symptoms. However, invasiveness, discomfort resulting from carrying an external device, and side effects associated with the way of administration limit its application in PD patients. At present, there are no guidelines that delineate to which patients LCIG should be offered as monotherapy, in combination with oral and/or transdermal medication, or as additional therapy to deep brain stimulation (DBS). Based on clinical studies, we propose an expert consensus for neurologists addressing the question when LCIG therapy should be recommended and in which cases LCIG infusion is suggested in combination with other antiparkinsonian drugs and/or DBS. We describe how LCIG should be initiated and what we consider necessary for clinical follow-up. We suggest an algorithm facilitating decision-making with respect to the currently available invasive PD therapies, namely infusion with subcutaneous apomorphine, LCIG, and DBS.
KW - Journal Article
U2 - 10.1007/s00702-017-1698-7
DO - 10.1007/s00702-017-1698-7
M3 - SCORING: Journal article
C2 - 28229223
VL - 124
SP - 1005
EP - 1013
JO - J NEURAL TRANSM
JF - J NEURAL TRANSM
SN - 0300-9564
IS - 8
ER -
